Abstract
Background Exposure to ambient air pollution is strongly associated with increased cerebrovascular diseases. The 2019–20 bushfire season in Australia burnt 5.4 million hectares of land in New South Wales alone, with smoke so severe it affected cities in Argentina, 11,000 km away. We aimed to determine the effects of i) short-term air pollution triggered by bushfires and ii) high smoke days in increasing the daily number of hospital admissions with cerebrovascular diseases.
Methods Hospitalisation data were accessed from the admitted patient dataset from seven local Government areas of Hunter New England Local Health District. The bushfire period was defined from 1 October 2019 to 10 February 2020, and a similar period from 2018-19 as the control. High bushfire smoke days were days when the average daily concentration of particulate matter was higher than the 95th percentile of the control period. Poisson regression models and fixed effect meta-analysis were used to analyse the data.
Results In total, 275 patients with cerebrovascular admissions were identified, with 147 (53.5%) during the bushfire (2019-20) and 128 (46.5%) in the control period (2018-19). There was no significant increase in daily cerebrovascular disease (Incidence Rate Ratio, IRR: 1.04; 95% CI: 0.98-1.05; p-value: 0.73) or ischemic stroke (IRR: 1.18; 95% CI: 0.87-1.59; p-value: 0.28) admissions over the entire bushfire period. However, the high bushfire smoke days were associated with increased ischaemic stroke-related hospital admissions with a lag of 0-1 days (IRR: 1.28; 95% CI: 1.01-1.62; I2=18.9%). In addition, during the bushfire period, particulate matter, both PM10 and PM2.5 (defined as particulates that have an effective aerodynamic diameter of 10 microns, and 2.5 microns, respectively), were also associated with increased ischaemic stroke admissions with a lag of 0 to 3 days.
Conclusion The results suggested an association between particulate matter and high smoke days with increased hospital admissions due to cerebrovascular diseases during the recent Australian bushfire season.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NA
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval was taken from the Hunter New England Health Human Research Ethics Committee (2020/ETH01801).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data that support the findings of this study are available on request from the corresponding author.
